{"entity":{"id":"nct04093167","kind":"trial","name":"Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer","aka":[],"tldr":"A phase 2/3 trial of pembrolizumab in lung cancer, run by Canadian Cancer Trials Group, active but no longer recruiting.","summary":"Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer is a phase 2/3, randomised interventional study registered as NCT04093167 by Canadian Cancer Trials Group, with a registry enrolment figure of 53 participants, started 2020-05-26 and due to reach its primary completion in 2026-12-31. Interventions recorded: Pembrolizumab. Conditions listed: Lung Cancer. Primary outcome: Stage 1: Concordance rate between molecular response and radiologic response; Stage 2: Phase II Progression-Free Survival (PFS); Stage 2: Phase III Overall Survival. Lung eligibility wording from the registry: \"* Histologically or cytologically confirmed metastatic NSCLC\". Sites: Canada, United States. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT04093167","url":"https://clinicaltrials.gov/study/NCT04093167"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["lung-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","mrd-testing"],"targets":[],"drugs":["pembrolizumab"],"companies":["cctg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04093167","phase":"2/3","setting":"A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer","sponsor":"Canadian Cancer Trials Group","enrolled":53,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04093167/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"cctg","kind":"company","name":"Canadian Cancer Trials Group (CCTG)","route":"/companies/cctg/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}